Plus Therapeutics Inc
PSTV
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.36M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.36 Million |
|---|---|
| Enterprise Value | $7.04 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-7.19 |
| Beta | 1.4 |
| Outstanding Shares | 6,773,125 |
Return
| Return on Equity | -477.54% |
|---|---|
| Return on Assets | -185.94% |
| Return on Invested Capital | 366.70% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | -3.87 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.44 |
| Enterprise Value to EBIT | 0.35 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
$1.11 M
Average shareholder expectationNext Earnings Call
Expected Date
August 19, 2026
EPS Estimate
$-0.79
Average shareholder expectationRevenue Estimate
$1.24 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.50%▼ 9.35% |
|---|---|
| Total Invested | $1.49M▼ 74.87% |
| Investors Holding | 22▼ 5.00% |
ESG Score
No data
About Plus Therapeutics Inc
2,018 employees
CEO: Marc Hedrick Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...